Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology

合并创建一家在纳斯达克上市的临床阶段生物制药公司，专注于推进OnKure在肿瘤学领域的新型精准药物组合

Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026

合并后的公司预计将拥有约1.2亿美元的现金资源，预计将通过多个临床里程碑提供资金，并进入2026年第四季度

IRVINE, Calif., and BOULDER, Colo., May 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

加利福尼亚州欧文市和科罗拉多州博尔德市，2024年5月13日（环球通讯社）--Reneo Pharmaceuticals，Inc.（纳斯达克：RPHM）和OnKure，Inc.，一家专注于开发新型精准肿瘤药物的私营临床阶段生物制药公司，今天宣布，他们已经签署了最终合并协议，将两家公司合并为全股票交易。

The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors. Upon completion of the transaction, the combined company is expected to operate under the name OnKure Therapeutics, Inc., and trade on the Nasdaq Global Market under the ticker symbol “OKUR”..

合并后的公司将专注于推进OnKure针对磷酸肌醇3-激酶α（PI3Kα）致癌突变的候选管道，包括其领先项目OKI-219，该项目目前正在进行实体瘤治疗的1期临床试验。交易完成后，合并后的公司预计将以OnKure Therapeutics，Inc.的名义运营，并在纳斯达克全球市场上以“OKUR”的股票代码进行交易。。

In connection with the transaction, Reneo Pharmaceuticals has entered into a subscription agreement for a $65 million private investment in public equity (PIPE) financing expected to close concurrently with the closing of the merger, with a group of institutional investors, including Acorn Bioventures, Cormorant Asset Management, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Surveyor Capital (a Citadel company), and Vestal Point Capital.

就交易而言，雷诺制药（Reneo Pharmaceuticals）与一群机构投资者签订了一份认购协议，以获得6500万美元的私人投资，用于公共股本（PIPE）融资，预计将在合并结束时同时完成，这些机构投资者包括Acorn Bioventures、Cormorant Asset Management、Deep Track Capital、Perceptive Advisors、Samsara BioCapital、Surveyor Capital（一家Citadel公司）和Vestal Point Capital。

The transactions are subject to stockholder approval by both companies, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission, a condition that Reneo Pharmaceuticals have at least $55 million in net cash at the closing (excluding proceeds from the concurrent PIPE financing), the continued listing of the combined company on Nasdaq, and satisfaction of other customary closing conditions..

这些交易需要得到两家公司的股东批准、向美国证券交易委员会提交的登记声明的有效性、雷诺制药在交割时拥有至少5500万美元净现金的条件（不包括同时进行的管道融资的收益）、合并公司在纳斯达克的继续上市以及其他惯常交割条件的满足。。

Including proceeds from the concurrent PIPE financing, the combined company is expected to have approximately $120 million of cash, cash equivalents, and short-term investments at closing. The merger and concurrent PIPE financing are expected to close in 2024.

包括并行管道融资的收益，合并后的公司预计在交割时将拥有约1.2亿美元的现金、现金等价物和短期投资。合并和并行管道融资预计将于2024年结束。

In February 2024, OnKure initiated a first-in-human clinical trial to evaluate OKI-219, a mutant-selective PI3KαH1047R inhibitor. The PIKture-01 trial is a Phase 1 dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of OKI-219 as a monotherapy in patients with advanced solid tumors and in combination with endocrine therapy or HER-2 targeted therapy in patients with advanced breast cancer..

2024年2月，OnKure启动了首次人体临床试验，以评估突变选择性PI3KαH1047R抑制剂OKI-219。PIKture-01试验是一项1期剂量递增试验，旨在评估OKI-219作为晚期实体瘤患者单药治疗的安全性，耐受性，药代动力学，药效学和疗效，并与内分泌治疗或HER-2靶向治疗联合用于晚期乳腺癌患者。。

“Following a thorough evaluation of strategic alternatives, the Reneo board of directors and management team believe that this anticipated transaction represents a compelling opportunity to deliver shareholder value as the OnKure team advances their PI3Kα inhibitors,” said Mike Grey, Executive Chairman and founder of Reneo Pharmaceuticals.

Reneo Pharmaceuticals执行董事长兼创始人迈克·格雷（MikeGrey）表示：“经过对战略替代方案的彻底评估，Reneo董事会和管理团队认为，随着OnKure团队开发PI3Kα抑制剂，这项预期的交易为股东带来了一个极具吸引力的机会。”。

“OnKure has an experienced team of drug developers, and we are excited about the potential for OKI-219 to become a meaningful treatment option for patients suffering from breast cancer.”.

“OnKure拥有一支经验丰富的药物开发团队，我们对OKI-219成为乳腺癌患者有意义的治疗选择的潜力感到兴奋。”。

“We are pleased to announce our proposed merger with Reneo Pharmaceuticals, allowing us to create a publicly traded company focused on advancing OnKure’s lead, mutant-specific programs targeting PI3Kα in breast cancer. This opportunity comes at an important time for OnKure as we recently initiated our PIKture-01 trial of OKI-219 and expect early clinical data in the fourth quarter of this year,” said Nicholas Saccomano, President and Chief Executive Officer of OnKure..

OnKure总裁兼首席执行官尼古拉斯·萨科马诺（NicholasSaccomano）表示：“我们很高兴宣布与Reneo Pharmaceuticals的拟议合并，这使我们能够创建一家上市公司，专注于推进OnKure针对乳腺癌PI3Kα的领先突变特异性计划。这一机会正值OnKure的重要时刻，因为我们最近启动了OKI-219的PIKture-01试验，预计今年第四季度会有早期临床数据。”。。

About PI3Kα and OKI-219

关于PI3Kα和OKI-219

PI3Kα is the most frequently mutated oncogene in cancers, and PI3KαH1047R is the most common mutation in this gene, being found in 15% of breast cancer and 4% of cancers overall. While novel drugs targeting PI3Kα have been approved, the lack of mutant selectivity of these therapeutics drives considerable on-target toxicity by inhibiting the normal version of this protein in various tissues.

PI3Kα是癌症中突变频率最高的癌基因，PI3KαH1047R是该基因中最常见的突变，在15%的乳腺癌和4%的癌症中发现。虽然靶向PI3Kα的新药已被批准，但这些疗法缺乏突变选择性，通过抑制该蛋白在各种组织中的正常形式，导致了相当大的靶向毒性。

To address this challenge, OnKure is discovering and developing a portfolio of highly mutant-selective PI3Kα inhibitors with the goal of improving efficacy and safety with molecules that fully inhibit the mutant oncogene while sparing the wild-type enzyme in normal tissues. OKI-219 is a potential best-in-class, orally bioavailable, highly selective inhibitor of PI3KαH1047R with approximately 80-fold selectivity for the mutated form of the enzyme compared to wild-type.

为了应对这一挑战，OnKure正在发现并开发一系列高度突变的选择性PI3Kα抑制剂，目的是提高完全抑制突变癌基因的分子的功效和安全性，同时在正常组织中保留野生型酶。OKI-219是一种潜在的同类最佳，口服生物可利用的高选择性PI3KαH1047R抑制剂，与野生型相比，对突变形式的酶具有约80倍的选择性。

OnKure believes that the wild-type-sparing properties of OKI-219 should significantly improve the activity and safety relative to currently approved agents. OKI-219 is currently in Phase 1 of clinical development in solid tumor patients with PI3KαH1047R mutations, including breast cancer..

OnKure认为，相对于目前批准的药物，OKI-219的野生型保留特性应能显着提高活性和安全性。OKI-219目前处于PI3KαH1047R突变的实体瘤患者（包括乳腺癌）的临床发展的第一阶段。。

About the Proposed Merger

关于拟议合并

Pre-merger Reneo stockholders are expected to own approximately 31% of the combined company, and pre-merger OnKure stockholders are expected to own approximately 69% of the combined company, upon the closing of the merger, exclusive of the PIPE financing. The percentage of the combined company that each company’s former stockholders are expected to own may be adjusted based on Reneo’s net cash at closing..

合并前Reneo股东预计拥有合并公司约31%的股份，合并前OnKure股东预计在合并结束时拥有合并公司约69%的股份，不包括管道融资。各公司前股东预计拥有的合并公司的百分比可能会根据雷诺收盘时的净现金进行调整。。

The transaction has been unanimously approved by the board of directors of both companies and is expected to close in 2024, subject to customary closing conditions, including approval by the stockholders of each company.

该交易已获得两家公司董事会的一致批准，预计将于2024年完成，但须符合惯例的交割条件，包括每家公司股东的批准。

Management and Organization

管理和组织

Following the merger, the combined company will be led by Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, and other members of the OnKure management team. Reneo Pharmaceuticals will be renamed “OnKure Therapeutics, Inc.” and the corporate headquarters will be located in Boulder, CO.

合并后，合并后的公司将由OnKure总裁兼首席执行官NicholasSaccomano博士以及OnKure管理团队的其他成员领导。Reneo Pharmaceuticals将更名为“OnKure Therapeutics，Inc.”，公司总部将位于科罗拉多州博尔德。

The merger agreement provides that the board of directors of the combined company will be composed of eight members, including six board members chosen by OnKure and two members from the legacy Reneo board..

合并协议规定，被合并公司的董事会将由八名成员组成，其中六名由OnKure选出的董事会成员和两名来自legacy Reneo董事会的成员。。

Advisors

顾问

Leerink Partners is acting as exclusive financial advisor to Reneo for the transaction. Jones Day and Cooley LLP are serving as legal counsel for Reneo. Leerink Partners, Evercore ISI and LifeSci Capital are serving as the placement agents for the PIPE financing. Covington & Burling LLP is serving as legal counsel to the placement agents in connection with the PIPE financing.

Leerink Partners担任Reneo的独家财务顾问。Jones Day和Cooley LLP担任Reneo的法律顾问。Leerink Partners、Evercore ISI和LifeSci Capital担任管道融资的配售代理。Covington&Burling LLP担任与管道融资相关的配售代理的法律顾问。

Oppenheimer & Co. is serving as capital markets advisor to OnKure. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to OnKure..

Oppenheimer&Co.担任OnKure的资本市场顾问。Wilson Sonsini Goodrich&Rosati，P.C.担任OnKure的法律顾问。。

About Reneo Pharmaceuticals

关于Reneo Pharmaceuticals

Reneo is a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate.

Reneo是一家制药公司，历史上专注于为患有罕见遗传性线粒体疾病的患者开发和商业化治疗，这些疾病通常与线粒体无法产生三磷酸腺苷有关。

About OnKure

关于OnKure

OnKure, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using structure-based drug design portfolio, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.

OnKure，Inc.是一家临床阶段的生物制药公司，专注于发现和开发一流的精密药物，这些药物针对的是经过生物学验证的癌症驱动因素，而这些癌症的现有疗法服务不足。使用基于结构的药物设计组合，OnKure正在构建一系列肿瘤不可知候选药物，旨在实现最佳疗效和耐受性。

OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene..

OnKure目前正在开发选择性PI3KαH1047R抑制剂OKI-219作为其主要项目。OnKure旨在成为靶向致癌PI3Kα的领导者，并拥有多个程序，旨在实现这一关键致癌基因的最佳靶向。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed business combination involving Reneo and OnKure, the concurrent PIPE financing and any related proposed transactions (collectively, the “Proposed Transactions”).

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款所指的前瞻性声明，包括但不限于关于涉及Reneo和OnKure的拟议企业合并的结构、时间和完成情况、并行管道融资和任何相关拟议交易（统称“拟议交易”）的明示或暗示声明。

Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements generally are accompanied by words such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “future,” “goal,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seem,” “seek,” “should,” “target,” “will,” “would,” and similar expressions that indicate future events or trends or that are not statements of historical matters.

本新闻稿中包含的任何非历史事实声明均可被视为前瞻性声明。前瞻性陈述通常伴随着“预期”、“相信”、“继续”、“估计”、“期望”、“未来”、“目标”、“打算”、“可能”、“展望”、“计划”、“潜力”、“预测”、“项目”、“看起来”、“寻求”、“应该”、“目标”、“将会”、“将会”等词，以及类似的表达方式，这些表达方式表明未来的事件或趋势，或者不是历史事件的陈述。

These forward-looking statements may include, but are not limited to, statements regarding the Proposed Transactions; the combined company’s capitalization and the planned use of proceeds following the Proposed Transactions; the potential of, and plans and expectations regarding, the combined company’s product candidates; the expected executive officers and directors of the combined company; the development of the combined company’s current and future product candidates; the future operations of Reneo, OnKure and the combined company; and the commercial potential of the combined company’s product candidates, including any anticipated milestones.

这些前瞻性声明可能包括但不限于有关拟议交易的声明；合并公司的资本化和拟议交易后收益的计划用途；合并公司候选产品的潜力、计划和期望；被合并公司的预期高级管理人员和董事；合并公司当前和未来候选产品的开发；Reneo、OnKure和合并公司的未来运营；以及合并后公司候选产品的商业潜力，包括任何预期的里程碑。

.

.

These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Reneo’s and OnKure’s management and are not assurances as to actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

这些声明基于各种假设，无论是否在本新闻稿中确定，以及Reneo和OnKure管理层目前的期望，并不是对实际业绩的保证。这些前瞻性陈述仅用于说明目的，不打算作为担保、保证、预测或事实或概率的确定性陈述，任何投资者都不得依赖这些前瞻性陈述。

Actual events and circumstances, many of which are outside of the control of Reneo and OnKure, are difficult or impossible to predict and will differ from assumptions underlying forward-looking statements..

实际事件和情况（其中许多不在Reneo和OnKure的控制范围内）很难或不可能预测，并且与前瞻性陈述的假设不同。。

These forward-looking statements are subject to a number of risks and uncertainties, including, among other things: the risk that the conditions to the closing of the Proposed Transactions are not satisfied, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect Reneo, OnKure or the combined company or that the approval of the stockholders of Reneo or OnKure is not obtained on the timeline expected, if at all; uncertainties as to the timing of the closing of the Proposed Transactions and the ability of each of Reneo and OnKure to consummate the Proposed Transactions; risks related to the ability of Reneo and OnKure to correctly estimate and manage their respective operating expenses and expenses associated with the Proposed Transactions pending the closing of the Proposed Transactions; risks associated with the possible failure to realize certain anticipated benefits of the Proposed Transactions, including with respect to future financial and operating results; the potential for the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Proposed Transactions and any agreements entered into in connection therewith; the possible effect of the announcement, pendency or completion of the Proposed Transactions on Reneo’s or OnKure’s business relationships, operating results and business generally; the risk that as a result of adjustments to the exchange ratio, Reneo stockholders and OnKure stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Reneo’s common stock relative to the value suggested by the exchange ratio; unexpected costs, charges.

这些前瞻性陈述受到许多风险和不确定性的影响，其中包括：未满足拟议交易结束条件的风险，包括未获得任何必要的监管批准、延迟或受到可能对Reneo、OnKure或合并公司产生不利影响的意外条件的风险，或者Reneo或OnKure股东的批准未能在预期的时间内获得（如果有的话）；拟议交易的交割时间以及Reneo和OnKure各自完成拟议交易的能力存在不确定性；与Reneo和OnKure在拟定交易结束之前正确估计和管理其各自的运营费用和与拟定交易相关的费用的能力有关的风险；与可能无法实现拟议交易的某些预期收益相关的风险，包括与未来财务和经营成果相关的风险；发生任何事件、变化或其他情况或条件的可能性，这些事件、变化或其他情况或条件可能导致拟定交易和与之相关的任何协议终止；拟议交易的宣布、未决或完成对Reneo或OnKure的业务关系、经营成果和业务的可能影响；由于汇率调整，Reneo股东和OnKure股东可能拥有比目前预期更多或更少的合并公司的风险；与雷诺普通股市场价格相关的风险，相对于汇率建议的价值；意外成本、费用。

This press release also concerns product candidates that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. Such product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated..

本新闻稿还涉及正在进行临床研究且尚未获得美国食品和药物管理局批准上市的候选产品。这些候选产品目前仅限于联邦法律的研究用途，并且没有就其安全性或有效性进行任何陈述。。

Additional Information and Where to Find It

其他信息以及在哪里可以找到它

The information herein does not purport to be all-inclusive or contain all the information that may be required to make a full analysis of Reneo, OnKure, the combined company or the Proposed Transactions. Readers should each make their own evaluation of Reneo and OnKure and of the relevance and adequacy of the information disclosed herein and made available elsewhere by Reneo and OnKure, as described below, and should make such other investigations as they deem necessary..

此处的信息并不包含对Reneo、OnKure、合并公司或拟议交易进行全面分析所需的所有信息。读者应各自对Reneo和OnKure以及本文披露的信息的相关性和充分性进行评估，并应进行他们认为必要的其他调查。。

This press release may be deemed to be solicitation material in respect of the Proposed Transactions. In connection with the Proposed Transactions, Reneo will file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus.

本新闻稿可能被视为与拟议交易有关的招标材料。就拟议交易而言，雷诺将向美国证券交易委员会提交相关材料，包括S-4表格（“S-4表格”）上的注册声明，其中将包含一份代理声明（“代理声明”）和招股说明书。

This press release is not a substitute for the Form S-4, the Proxy Statement or for any other document that Reneo may file with the SEC and/or send to Reneo’s stockholders in connection with the Proposed Transactions. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF RENEO AND ONKURE ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT RENEO, ONKURE, THE COMBINED COMPANY, THE PROPOSED TRANSACTIONS AND RELATED MATTERS..

本新闻稿不能替代S-4表格、委托书或雷诺可能向SEC提交和/或发送给雷诺股东的与拟议交易有关的任何其他文件。在做出任何投票决定之前，请RENEO和ONKURE的投资者和证券持有人仔细阅读S-4表、委托书和其他提交给SEC的文件，因为这些文件包含有关RENEO、ONKURE、合并公司、拟议交易和相关事项的重要信息。。

Investors and security holders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Reneo with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Reneo with the SEC will also be available free of charge on Reneo’s website at www.reneopharma.com/investors or by contacting Reneo’s Investor Relations at investors@reneopharma.com..

投资者和证券持有人可以通过美国证券交易委员会网站www.SEC.gov免费获得雷诺向美国证券交易委员会提交的S-4表、委托书和其他文件的副本。雷诺向美国证券交易委员会提交的文件副本也可以在雷诺的网站www.reneopharma.com/Investors免费获得，也可以通过联系雷诺的投资者关系网站www.reneopharma.com/Investors免费获得investors@reneopharma.com..

Participants in the Solicitation

征集参与者

Reneo, OnKure and their respective directors and certain of their executive officers may be considered participants in the solicitation of proxies from Reneo’s stockholders with respect to the Proposed Transactions under the rules of the SEC. Information about the directors and executive officers of Reneo and their ownership of common stock of Reneo is set forth in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 28, 2024, as amended on April 26, 2024, including under the sections entitled “Item 10.

Reneo、OnKure及其各自的董事和某些高管可能被视为根据SEC规则就拟议交易向Reneo股东征集代理人的参与者。关于Reneo董事和高管及其对Reneo普通股所有权的信息载于截至2023年12月31日的年度报告10-K表格中，该表格于2024年3月28日提交SEC，并于2024年4月26日修订，包括标题为“项目10”的章节。

Directors, Executive Officers and Corporate Governance”, “Item 11. Executive Compensation”, “Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters”, and “Item 13. Certain Relationships and Related Transactions, and Director Independence”. To the extent the security holdings of directors and executive officers of Reneo have changed since the amounts described in this filing, such changes are set forth on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, which can be found at no charge at the SEC’s website at www.sec.gov.

董事、执行官和公司治理”，第11项。高管薪酬”，“第12项。某些受益所有人和管理层的担保所有权以及相关股东事项”，以及“第13项”。某些关系和关联交易，以及董事的独立性”。如果Reneo董事和执行官的证券持有量自本文件所述金额以来发生了变化，则此类变化载于向美国证券交易委员会提交的表格3中的初始实益所有权声明或表格4中的所有权变更声明中，可在美国证券交易委员会网站www.SEC.gov上免费找到。

In addition, certain of Reneo’s executive officers are expected to provide consulting services to the combined company following the closing of the Mergers. Additional information regarding the persons who may be deemed participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available.

此外，预计雷诺的某些高管将在合并结束后为合并后的公司提供咨询服务。有关可能被视为委托书征集参与者的其他信息，以及通过证券持有或其他方式对其直接和间接利益的描述，也将包含在S-4表格、委托书声明和其他相关材料中，这些材料将在可用时提交给SEC。

You may obtain free copies of this document as described above..

如上所述，您可以免费获得本文件的副本。。

OnKure and its directors and executive officers, which consist of R. Michael Carruthers, Isaac Manke, Ph.D., Andrew Phillips, Ph.D., who are the non-employee members of the OnKure board of directors, Nicholas A. Saccomano, Ph.D., OnKure’s President and Chief Executive Officer and a member of the OnKure board of directors, and Jason Leverone, OnKure’s Chief Financial Officer, may be deemed to be participants in the solicitation of proxies from Reneo stockholders in connection with the Proposed Transactions.

OnKure及其董事和执行官，包括R.Michael Carruthers、Isaac Manke博士、Andrew Phillips博士，他们是OnKure董事会的非员工成员，Nicholas A.Saccomano博士，OnKure总裁兼首席执行官兼OnKure董事会成员，以及Jason Leverone，OnKure首席财务官，可能被视为Reneo股东就拟议交易征集代理人的参与者。

In the Proposed Transactions, certain outstanding, unvested equity awards held by Dr. Saccomano will become fully vested. Following the closing of the Proposed Transactions, Dr. Saccomano and Mr. Leverone will be named the President and Chief Executive Officer and Chief Financial Officer, respectively, of Reneo.

在拟议的交易中，Saccomano博士持有的某些未兑现的未授予股权将全部授予。拟议交易结束后，萨科马诺博士和勒沃内先生将分别被任命为雷诺的总裁、首席执行官和首席财务官。

Additional information about the OnKure directors and executive officers, including their direct and indirect interests in Reneo, by security holdings or otherwise, will be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available.

有关OnKure董事和执行官的其他信息，包括他们通过证券持有或其他方式在Reneo中的直接和间接权益，将包含在S-4表格、委托书和其他相关材料中，这些材料将在可用时提交给SEC。

That document can be obtained free of charge from the sources indicated above..

该文件可从上述来源免费获得。。

No Offer or Solicitation

无要约或招揽

This press release is for informational purposes only and is neither an offer to sell, nor a solicitation of an offer to buy or subscribe for, any securities of Reneo or OnKure, nor is it a solicitation of any vote in any jurisdiction with respect to the Proposed Transactions or otherwise.

本新闻稿仅供参考，既不是出售Reneo或OnKure任何证券的要约，也不是购买或认购Reneo或OnKure任何证券的要约，也不是在任何司法管辖区就拟议交易或其他方面进行任何投票的邀约。

Contacts:

联系人：

Danielle Spangler

丹妮尔·斯潘格勒

Investor Relations

投资者关系

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals，股份有限公司。

dspangler@reneopharma.com

dspangler@reneopharma.com

Investor Relations

投资者关系

OnKure, Inc.

OnKure，股份有限公司。

investors@OnKure.com

investors@OnKure.com